For improvement of post prandialhyperglycaemia in diabetic mellitus only when diet and/or excercise or oral hypoglycemic drugs or insulin preparations in addition to diet and /or excercise do not result adequate glycaemic control.
Voglibose is an alpha-glucosidase inhibitor which reduces intestinal absorption of starch,dextrin, and disaccharides by inhibiting the action of alpha-glucosidase in the intestinal brush border. Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose.
Voglibose tablets are orally administered in a single dose of 0.2 mg, 3 times a day, before each meal. If the effect is not sufficient, the quantity of a single dose may be increased up to 0.3 mg.
Contraindicated in patients with known hypersensitivity to the drug,acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
Voglibose should be administered with caution to the following patients: patients with history of laparotomy or ileus; patients with chronic intestinal disease accompanied by disturbance in digestion and absorption; patients with aggravating symptoms due to increased generation of intestinal gas.
There are no adequate and well-controlled studies in pregnancy women,nursing womenandchildren.
When voglibose is used in combination with derivative(s) of sulfonylamide, sulfonylurea or biguanide, or with insulin, hypoglycemic symptoms may occur.
Gastrointestinal adverse effects such as diarrhoea, loose stools, abdominal pain, constipation, anorexia, nausea, vomiting, or heartburn may occur with the use of Voglibose.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS